Hair loss concerns and treatments like Minoxidil and Finasteride are humorously discussed. The community's quirks and dedication to battling hair loss are highlighted.
Fluorescent lighting makes hair look thinner, causing concern about appearance. Some users consider treatments like DUT, while others share experiences of hair looking better in different lighting or conditions.
Finasteride and dutasteride may increase estrogen levels, leading to water retention and a fuller face. Users discuss managing these effects with lifestyle changes and supplements like zinc and DIM.
A user shared their experience with hair regrowth using supplements like NAC and DIM, and briefly using minoxidil with microneedling. They reported some improvement in hair density, but the community questioned the effectiveness compared to traditional treatments like finasteride.
Peptides like TB500, KPV, GHK-CU, and BPC-157 are overhyped for hair growth with limited proven effectiveness in humans. Combining peptides with delivery methods like iontophoresis and sonophoresis shows promise, but many claims remain unproven.
A person dealing with hair loss is considering shaving their head, using scalp micropigmentation to cover a FUT scar, or trying a hair system. They are also contemplating treatments like minoxidil, finasteride, and dutasteride.
Comparing the effectiveness and side effects of topical finasteride versus oral finasteride, with people sharing their experiences using both treatments to manage hair loss.
.
ummwhatsure: No it doesn't. I started losing my hair around 27/28.
This user has had great success with a combination of finasteride and Minoxidil, taking 1 milligram of finasteride per day and applying Minoxidil twice daily for 4 years, starting when they were 31. They experienced some shedding in the first two years, but now have thicker, fuller hair than before.
Vitamin C mixed with shampoo stopped shedding and promoted hair regrowth after 1.5 years. Both the person and their wife experienced significant hair loss reduction with this method.
Ultrasound imaging can predict hair shedding and assess hair growth stages by analyzing hair follicle characteristics. The conversation also discusses using ultrasound for personal hair analysis and mentions the potential use of infrared emission for hair treatment.
Finasteride and Nizoral shampoo with Ketoconazole are used for hair loss treatment. Liquid Chromatography–Mass Spectrometry (LC-MS) is recommended over Enzyme-Linked Immunosorbent Assay (ELISA) for more accurate DHT testing.
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
High frequency ultrasonography and HR-MRI can help identify hair shedding causes like inflammation and fibrosis. The conversation discusses the potential of using these technologies to evaluate treatments like Verteporfin for hair regeneration.
A user bought questionable RU58841 powder from AliExpress and seeks a way to test its composition in Europe. Another user suggests using Janoshik for testing.
The conversation is about a user trying to fund lab testing for RU58841 to verify its legitimacy, as there are doubts about its effectiveness. Some users express skepticism about RU58841, suggesting alternatives like KX-826.
Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.
Two Chinese suppliers provided legitimate RU58841, confirmed through a free drug testing service. The vendors were Shaanxi Greenyo Biotech and Lyphar, found on Made-in-China.
A man stopped taking finasteride, a hair loss treatment, to improve his fertility. His sperm count and motility increased after stopping the medication, but sperm shape did not change.
The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.